Divamics
Suzhou, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
AI-driven drug discovery company using molecular dynamics and AI to design novel therapeutics for autoimmune and metabolic diseases.
ImmunologyMetabolic
Technology Platform
BioTrajectory AI platform combining multi-scale molecular dynamics simulations with proprietary AI algorithms to model protein-ligand interactions and accelerate drug design for challenging targets.
Opportunities
Growing demand for AI-driven drug discovery solutions and partnerships with global biopharma companies seeking to accelerate early-stage R&D; potential to license multiple preclinical assets across different therapeutic areas.
Risk Factors
Heavy competition in AI drug discovery space with well-funded global players; unproven platform validation through clinical success; reliance on partnership revenue model in pre-revenue stage.
Competitive Landscape
Competes with Schrödinger, Recursion, Insilico Medicine globally and XtalPi, Crystalwise in China; differentiates through physics-based molecular dynamics simulations enhanced by AI rather than purely data-driven approaches.